Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, issued a statement on April 7, 2026, applauding the U.S. Food and Drug Administration (FDA) approval of Eli Lilly’s Foundayo, the latest oral GLP-1 receptor agonist for chronic weight management in adults.
The approval of Foundayo marks a significant milestone in the metabolic health sector, increasing the number of available oral GLP-1 brands to three.
Lexaria highlighted Foundayo’s impressive clinical profile, which demonstrated an average weight loss of 27.3 lb (12.4%) over a 72-week period in its pivotal registrational trials.
Lexaria, which is developing its proprietary DehydraTECH™ technology to enhance the performance of GLP-1 drugs, views the expansion of the oral market as a major validation of its own strategic focus.
The company notes that while oral options are becoming more prevalent, patient adherence remains a challenge due to gastrointestinal side effects—a specific area where Lexaria’s technology has shown potential for significant improvement.
Lexaria cited data from its recent human pilot study, GLP-1-H24-4, which compared DehydraTECH-processed semaglutide to the established brand Rybelsus®.
The study results indicated that DehydraTECH led to 47.9% fewer adverse events than the conventional formulation.
By reducing the severity and frequency of side effects, Lexaria aims to enable higher dosing levels and improved long-term patient compliance.
The company currently holds 65 issued patents globally, covering various aspects of its dehydration-processing technology.
Throughout 2026, Lexaria plans to initiate additional GLP-1 testing to further evaluate the onset and duration of action for oral formulations enhanced by DehydraTECH.